Ashby J, Lefevre P A, Burlinson B, Penman M G
Mutat Res. 1985 Apr-May;156(1-2):1-18. doi: 10.1016/0165-1218(85)90002-3.
The in vivo rat hepatocyte autoradiographic assay for unscheduled DNA synthesis (UDS) described by Mirsalis et al, and its in vitro counterpart described earlier by Williams have been employed by us for 4 years. Our experience is that the in vivo assay performs as described in the literature. We have therefore concentrated in this initial paper on the key practical factors we have found to govern the assay sensitivity and reproducibility. This has been achieved by a discussion of the assay performance with two potent rat hepatocarcinogens [the novel azo compound 6-dimethylaminophenylazobenzthiazole (6BT) and the reference agent 2-acetylaminofluorene (2AAF)] and a non-carcinogen of similar structure to 6BT [5-dimethylaminophenylazoindazole (51)]. Assay responses were compared with the effect of these chemicals in the Salmonella mutation assay. We conclude that the in vivo liver UDS assay has a critical role to play as a complement to rodent bone marrow cytogenic assays when conducting assessment studies on agents defined as genotoxic in vitro. However, the in vivo assay is resource-consuming and false results could consequently arise due to incomplete evaluations. Methods to counteract this danger are discussed and criteria for assessing weak UDS responses are suggested.
我们采用Mirsalis等人描述的用于非程序性DNA合成(UDS)的体内大鼠肝细胞放射自显影测定法及其Williams早些时候描述的体外对应方法已有4年。我们的经验是,体内测定法的表现与文献中描述的一致。因此,在这篇初始论文中,我们集中讨论了我们发现的决定测定法灵敏度和可重复性的关键实际因素。这是通过讨论两种强效大鼠肝癌致癌物[新型偶氮化合物6 - 二甲基氨基苯基偶氮苯并噻唑(6BT)和参比剂2 - 乙酰氨基芴(2AAF)]以及一种结构与6BT相似的非致癌物[5 - 二甲基氨基苯基偶氮吲唑(5I)]的测定法性能来实现的。将测定反应与这些化学物质在沙门氏菌突变试验中的效果进行了比较。我们得出结论,在对体外定义为具有遗传毒性的试剂进行评估研究时,体内肝脏UDS测定法作为啮齿动物骨髓细胞遗传学测定法的补充具有关键作用。然而,体内测定法消耗资源,因此可能由于评估不完整而产生错误结果。讨论了应对这种风险的方法,并提出了评估微弱UDS反应的标准。